The unique mechanism of action of H01 (Hymecromone) allows it to bridge the gap between post-infection anti-virals and late-stage immune suppressants in the COVID-19 landscape. By reducing hyaluronan synthesis and accumulation, H01 could promote blood oxygenation and may prevent hyperinflammatory respiratory distress
The long history of tolerability of H01 across the globe supports widespread administration. H01 is suitable for use both in and out of hospital settings. The INHALE study aims to repurpose H01 for COVID-19 associate respiratory distress
Copyright © 2020 The INHALE Study - All Rights Reserved.